{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:39:34Z","timestamp":1758587974804,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.therap.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T11:36:07Z","timestamp":1558006567000},"page":"314-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Profil d\u2019acceptabilit\u00e9 de l\u2019antimoniate de m\u00e9glumine (Glucantime\u00ae) par voie parent\u00e9rale chez le nourrisson trait\u00e9 pour leishmaniose cutan\u00e9e"],"prefix":"10.1016","volume":"75","author":[{"given":"Fatma","family":"Frikha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Boudaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emna","family":"Bahloul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meriem","family":"Amouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamida","family":"Turki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2019.05.001_bib0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.05.001_bib0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4269\/ajtmh.2011.10-0002","article-title":"Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults","volume":"84","author":"Layegh","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.therap.2019.05.001_bib0090","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4269\/ajtmh.1999.61.766","article-title":"High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients","volume":"61","author":"Delgado","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.therap.2019.05.001_bib0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medmal.2004.07.032","article-title":"Glucantime\u00ae par voie parent\u00e9rale\u00a0: b\u00e9n\u00e9fice versus toxicit\u00e9","volume":"35","author":"Masmoudi","year":"2005","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.therap.2019.05.001_bib0100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jpids\/piu021","article-title":"Systemic meglumine antimoniate in cutaneous leishmaniasis of children: clinical and laboratory complications","volume":"4","author":"Layegh","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.therap.2019.05.001_bib0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.880090510","article-title":"Distribution of capillaries in normal and diseased human skeletal muscle","volume":"9","author":"Carry","year":"1986","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.therap.2019.05.001_bib0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1651-2227.1979.tb05030.x","article-title":"Pharmacokinetics of amikacin in infants and pre-school children","volume":"68","author":"Kafetzis","year":"1979","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.therap.2019.05.001_bib0115","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1086\/510860","article-title":"Pharmacokinetics of antimony in children treated for Leishmaniasis with meglumine antimoniate","volume":"195","author":"Cruz","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.therap.2019.05.001_bib0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology \u2014 Drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2019.05.001_bib0125","first-page":"499","article-title":"Effets ind\u00e9sirables du traitement syst\u00e9mique de la leishmaniose cutan\u00e9e par Glucantime\u00a0: exp\u00e9rience Tunisienne","volume":"68","author":"Mlika","year":"2008","journal-title":"Med Trop"},{"key":"10.1016\/j.therap.2019.05.001_bib0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S0074-02762003000100019","article-title":"High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls","volume":"98","author":"Romero","year":"2003","journal-title":"Mem Inst Oswaldo Cruz"},{"year":"2014","series-title":"Manuel pour la prise en charge de la leishmaniose cutan\u00e9e dans la R\u00e9gion OMS de la M\u00e9diterran\u00e9e orientale","author":"Organisation mondiale de la sant\u00e9 (OMS)","key":"10.1016\/j.therap.2019.05.001_bib0135"},{"key":"10.1016\/j.therap.2019.05.001_bib0140","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jir816","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children","volume":"205","author":"Rubiano","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.therap.2019.05.001_bib0145","first-page":"CR290","article-title":"Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children","volume":"15","author":"Shahian","year":"2009","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.therap.2019.05.001_bib0075","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1086\/510860","article-title":"Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate","volume":"195","author":"Cruz","year":"2007","journal-title":"J Infect Dis"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:10Z","timestamp":1758567250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719300721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0040595719300721"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2019.05.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profil d\u2019acceptabilit\u00e9 de l\u2019antimoniate de m\u00e9glumine (Glucantime\u00ae) par voie parent\u00e9rale chez le nourrisson trait\u00e9 pour leishmaniose cutan\u00e9e","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}